Claude Nicaise - 10 Mar 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Director
Signature
/s/ Cristin Rothfuss, as Attorney-in-Fact for Claude Nicaise
Issuer symbol
SRPT
Transactions as of
10 Mar 2025
Net transactions value
$0
Form type
4
Filing time
11 Mar 2025, 20:00:05 UTC
Previous filing
26 Jun 2024
Next filing
13 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Award +2,383 +13% 20,557 10 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRPT Stock Options (right to buy) Award $0 +4,792 +30% $0.000000 20,557 10 Mar 2025 Common Stock 4,792 $99.69 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026.